Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 35 - 80 |
| Updated: | 5/5/2014 |
| Start Date: | November 2011 |
| End Date: | July 2012 |
| Contact: | Paul Christian Schulze, MD, PhD |
| Email: | pcs2121@columbia.edu |
| Phone: | 212-305-6916 |
Effects of Glutamine and Fish Oil on Muscle Function in Heart Failure (GlutFish-HF)
The aim of this study is to determine whether supplementation of glutamine and fish oil can
improve peripheral skeletal muscle function and metabolism in patients with heart failure.
The investigators propose a randomized, double-blind, placebo controlled study comparing the
combined supplementation of fish oil and glutamine with placebo in patients with stable
heart failure. 38 patients with heart failure will be randomized to either receiving 6.5 g
fish oil/d and 8 g glutamine/d (n=19) or placebo (n=19) for 90 days. The primary outcome in
this study is the change in muscle functional capacity measured as changes in maximum muscle
strength and fatigability, peak VO2 and exercise time after supplementation. A secondary
outcome is the measurement of systemic and local markers of inflammation.
improve peripheral skeletal muscle function and metabolism in patients with heart failure.
The investigators propose a randomized, double-blind, placebo controlled study comparing the
combined supplementation of fish oil and glutamine with placebo in patients with stable
heart failure. 38 patients with heart failure will be randomized to either receiving 6.5 g
fish oil/d and 8 g glutamine/d (n=19) or placebo (n=19) for 90 days. The primary outcome in
this study is the change in muscle functional capacity measured as changes in maximum muscle
strength and fatigability, peak VO2 and exercise time after supplementation. A secondary
outcome is the measurement of systemic and local markers of inflammation.
Inclusion Criteria:
- age greater than 18 years,
- left ventricular ejection fraction less than or equal to 35%,
- stable on standard HF medications, and
- optimal medical therapy.
Exclusion Criteria:
- major cardiovascular events,
- procedures in the last 6 months,
- dementia,
- presence of cardiovascular diseases that may lead to harm if the patient took part in
the study (congenital heart disease, long QT syndrome, hypertrophic cardiomyopathy,
active myocarditis).
We found this trial at
1
site
Click here to add this to my saved trials
